Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Dosing decisions for replacement coagulation factors in patients with haemophilia should be made on an individual patient basis, with the required dose dependent on factors including the clinical situation, the severity of the factor deficiency, and the location and extent of bleeding. Moreover, there is considerable variability in the pharmacokinetics of coagulation products that needs to be considered; in particular, with both factor (F) IX and FVIII products, there is considerable inter-patient variability in in vivo recovery and terminal half-life values. In the present report, we provide a practical guide to calculating and applying pharmacokinetic parameters relevant to the optimal dosing of coagulation products. We discuss the conduct of a pharmacokinetic study in an individual patient, how to calculate pharmacokinetic values from raw data and clinical situations where an individual pharmacokinetic study is helpful. We highlight the importance of considering an individual pharmacokinetic study in all patients starting a new coagulation product.
Shapiro
A D
AD
Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, IN 46260, USA. ashapiro@ihtc.org
Korth-Bradley
J
J
Poon
M-C
MC
D001800:Blood Specimen Collection / Q000379:methods; D002648:Child; D003029:Coagulants / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D005164:Factor IX / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics; D005169:Factor VIII / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D012984:Software; D009626:Terminology as Topic
D003029:Coagulants; D005169:Factor VIII; D005164:Factor IX